This leads to relatively smooth (though not flawless) northbound trajectories and strong returns for most stocks over a ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

Re “The cops were Black. But acquitting the officers involved with Tyre Nichols death was racial” (column, May 11): LAPD ...

Stifel kept a Hold rating with a $194 target, focusing on the promising early prescription data for Journavx and the critical Phase 3 program for suzetrigine, a treatment for diabetic peripheral ...

Early prescription data for Journavx appears promising ... Stifel analysts emphasized the importance of Vertex’s pipeline, including the Phase 3 program for suzetrigine, which could significantly ...